Hologic/$HOLX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Hologic
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Ticker
$HOLX
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
7,063
ISIN
US4364401012
Website
Hologic Metrics
BasicAdvanced
$15B
27.97
$2.39
0.55
-
Price and volume
Market cap
$15B
Beta
0.55
52-week high
$84.67
52-week low
$51.90
Average daily volume
2.8M
Financial strength
Current ratio
3.242
Quick ratio
2.294
Long term debt to equity
53.511
Total debt to equity
54.507
Interest coverage (TTM)
7.76%
Profitability
EBITDA (TTM)
1,252.3
Gross margin (TTM)
61.06%
Net profit margin (TTM)
13.83%
Operating margin (TTM)
23.72%
Effective tax rate (TTM)
18.29%
Revenue per employee (TTM)
$570,000
Management effectiveness
Return on assets (TTM)
6.92%
Return on equity (TTM)
11.77%
Valuation
Price to earnings (TTM)
27.968
Price to revenue (TTM)
3.837
Price to book
3.23
Price to tangible book (TTM)
47.03
Price to free cash flow (TTM)
15.926
Free cash flow yield (TTM)
6.28%
Free cash flow per share (TTM)
419.76%
Growth
Revenue change (TTM)
1.66%
Earnings per share change (TTM)
25.36%
3-year revenue growth (CAGR)
-9.27%
10-year revenue growth (CAGR)
4.55%
3-year earnings per share growth (CAGR)
-26.64%
10-year earnings per share growth (CAGR)
19.37%
What the Analysts think about Hologic
Analyst ratings (Buy, Hold, Sell) for Hologic stock.
Bulls say / Bears say
Hologic's acquisition of Gynesonics for $350 million enhances its GYN Surgical portfolio, adding the Sonata System for minimally invasive uterine fibroid treatment, aligning with the company's strategy to expand in women's health. (Nasdaq)
The company is set to launch the Envision Mammography Platform, featuring a 2.5-second scan time, and the Genius AI Detection PRO solution, aiming to improve cancer detection and workflow efficiency. (Nasdaq)
Hologic's international surgical business achieved over 20% growth in the first quarter of fiscal 2025, indicating successful global market expansion. (Nasdaq)
The FDA issued a warning against using Hologic's BioZorb radiographic markers due to reports of serious adverse events, leading to a recall and potential reputational damage. (MedTech Dive)
Hologic plans to lay off 86 employees and close its Danbury, Connecticut facility by early 2025, which may indicate operational challenges or restructuring costs. (MedTech Dive)
Needham & Company LLC downgraded Hologic's stock rating to 'Hold,' suggesting potential concerns about the company's future performance. (WKRB News)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
Hologic Financial Performance
Revenues and expenses
Hologic Earnings Performance
Company profitability
Hologic News
AllArticlesVideos
Hologic to Announce Financial Results for the Third Quarter of Fiscal 2025 on Wednesday, July 30, 2025
Business Wire·1 week ago
Hologic Joins NEST Governance Committee to Advance the Use of Real-World Data in Medical Device Evaluation
Business Wire·1 month ago
Hologic reportedly rejects $16B go-private offer from TPG, Blackstone
Proactive Investors·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Hologic stock?
Hologic (HOLX) has a market cap of $15B as of July 12, 2025.
What is the P/E ratio for Hologic stock?
The price to earnings (P/E) ratio for Hologic (HOLX) stock is 27.97 as of July 12, 2025.
Does Hologic stock pay dividends?
No, Hologic (HOLX) stock does not pay dividends to its shareholders as of July 12, 2025.
When is the next Hologic dividend payment date?
Hologic (HOLX) stock does not pay dividends to its shareholders.
What is the beta indicator for Hologic?
Hologic (HOLX) has a beta rating of 0.55. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.